Pyr-AI

Last updated

Pyr-AI
Pyrrolidinylindane.svg
Clinical data
Other names2-PYI; 2-Pyrrolidinylindane; 1-(2-Indanyl)pyrrolidine; Compound 10j
Drug class Stimulant
ATC code
  • None
Identifiers
  • 1-(2,3-dihydro-1H-inden-2-yl)pyrrolidine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
Formula C13H17N
Molar mass 187.286 g·mol−1
3D model (JSmol)
  • C1CCN(C1)C2CC3=CC=CC=C3C2
  • InChI=1S/C13H17N/c1-2-6-12-10-13(9-11(12)5-1)14-7-3-4-8-14/h1-2,5-6,13H,3-4,7-10H2
  • Key:PAOQQDSGNKTTRU-UHFFFAOYSA-N

Pyr-AI, also known as 2-pyrrolidinylindane (2-PYI), is a stimulant drug of the 2-aminoindane family. [1] It is the analogue of 2-aminoindane (2-AI) in which the amine has been replaced with a pyrrolidine group. [1] The drug has been described as having strong and long-lasting amphetamine-like effects in rodents. [1] [2] Other 2-aminoindanes like 2-AI itself and NM-2-AI are known to act as potent monoamine releasing agents and reuptake inhibitors. [3] [4] Pyr-AI was first described in the scientific literature by 1973. [1] [2]

Contents

See also

References

  1. 1 2 3 4 Brandt SD, Braithwaite RA, Evans-Brown M, Kicman AT (2013). "Aminoindane Analogues". Novel Psychoactive Substances. Elsevier. pp. 261–283. doi:10.1016/b978-0-12-415816-0.00011-0. ISBN   978-0-12-415816-0 . Retrieved 2 November 2025. A 'strong amphetamine-type activity' has been reported for the pyrrolidine derivative of 2-AI (26, Fig. 11.10) [41] and 'a long duration' of activity was observed at the 10mg/kg dose in mice. Details about the procedure were not provided but neuropharmacological screenings were based on observational methods [48]. A piperidine derivative (27, PIP-AI), on the other hand, showed analgesic properties comparable to meperidine [41].
  2. 1 2 Solomons E, Sam J (December 1973). "2-Aminoindans of pharmacological interest". Journal of Medicinal Chemistry. 16 (12): 1330–1333. doi:10.1021/jm00270a004. PMID   4765859.
  3. ↑ Luethi D, Liechti ME (April 2020). "Designer drugs: mechanism of action and adverse effects". Archives of Toxicology. 94 (4): 1085–1133. Bibcode:2020ArTox..94.1085L. doi:10.1007/s00204-020-02693-7. PMC   7225206 . PMID   32249347.
  4. ↑ Halberstadt AL, Brandt SD, Walther D, Baumann MH (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". Psychopharmacology. 236 (3): 989–999. doi:10.1007/s00213-019-05207-1. PMC   6848746 . PMID   30904940.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.